
United States Patent and Trademark Office
- Sales Receipt -

11/25/2005 LHUMES 00000001 503493 10738404

01 FC:1806 180.00 DA

Ifw



## CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

November 9, 2005

Date

Shelley P.M. Fussey

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: ANTI-VEGF ANTIBODY PRODRUG

METHODS (As Amended)

Group Art Unit: 1642

Examiner: Joyce, C.

Atty. Dkt. No.: 3999.002587

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the document listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. The required copies are enclosed, although copies of U.S. patents are no longer required under 37 C.F.R. § 1.98(a)(2)(ii).

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the

receipt of a first Official Action reflecting an examination on the merits and hence is timely filed

in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be due in connection

herewith. Even if an Official Action had been issued, no fees would be required in light of the

following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed

in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent

office in a foreign counterpart to the present application. The listed documents were cited in an

Official Action on the merits in a co-pending application of one of the present inventors, U.S.

Application Serial No. 10/375,741 (Attorney Docket No. 4001.001999), apparently mailed from

the P.T.O. on August 10, 2005 (although not received until September 08, 2005), and could not

have been submitted before receipt. The present statement is being filed within three months of

the apparent mailing date of the referenced Official Action, and is thus timely.

No fees are due in connection with the filing of this Supplemental Information Disclosure

Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for

any reason, the Examiner should contact the undersigned representative to discuss deduction

from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/3999.002587.

Respectfully submitted

PEREGRINE PHARMACEUTICALS, INC.

Customer No. 000052101

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Agent for Applicants

5353 W. Alabama, Suite 306

Houston, Texas, 77056 (832) 886-5834

Date: November 9, 2005

2